[{"innerBlocks":[],"name":"core\/freeform","postId":639,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"Scientists at Carnegie Mellon University are using 3D printing to rebuild components of the heart, ranging from small blood vessels to moving ventricles.The researchers have developed an advanced version of what is known as the Freeform Reversible Embedding of Suspended Hydrogels, known as FRESH technology, to use collagen in 3D printing to create cardiac components with unprecedented complexity.Collagen is the most abundant protein in the body and the major component of connective tissues. While 3D bioprinting is not new technology, being able to achieve direct printing of living cells and soft biomaterials has been difficult, according to researchers.Also See:<\/b> 3D printing can aid surgery for multiple rib fractures<\/a>FRESH employs an embedded printing approach by using a temporary support gel that makes it possible to 3D print complex scaffolds\u2014a temporary platform\u2014using collagen in its native unmodified form. In the past, researchers have been limited because soft materials were difficult to print with high fidelity.\u201cWe now have the ability to build constructs that recapitulate key structural, mechanical and biological properties of native tissues,\u201d says Adam Feinberg, chief technology officer and co-founder of FluidForm, which holds the license to FRESH technology from Carnegie Mellon. \u201cThere are still many challenges to overcome to get us to bioengineered 3D organs, but this research represents a major step forward.\u201dWhile the heart was used for the proof of concept, FRESH printing of collagen and other soft biomaterials is a platform with potential to support advanced scaffold platforms for a range of other tissues and organ systems, Feinberg advises.Now, FluidForm will commercialize the FRESH technology with its first product, the Trileaflet heart valve, under the name LifeSupport bioprinting support gel.Francis Collins, MD, director at the National Institutes of Health, is impressed with the advancements being made at Carnegie Mellon. \u201cWhat distinguishes the new approach is its ability to print soft biological scaffolds that set the stage for the creation of custom-made tissues and organs with unprecedented anatomical detail,\u201d he says.The complete study is published in the current issue of Science, available here.","saveContent":"Scientists at Carnegie Mellon University are using 3D printing to rebuild components of the heart, ranging from small blood vessels to moving ventricles.The researchers have developed an advanced version of what is known as the Freeform Reversible Embedding of Suspended Hydrogels, known as FRESH technology, to use collagen in 3D printing to create cardiac components with unprecedented complexity.Collagen is the most abundant protein in the body and the major component of connective tissues. While 3D bioprinting is not new technology, being able to achieve direct printing of living cells and soft biomaterials has been difficult, according to researchers.Also See:<\/b> 3D printing can aid surgery for multiple rib fractures<\/a>FRESH employs an embedded printing approach by using a temporary support gel that makes it possible to 3D print complex scaffolds\u2014a temporary platform\u2014using collagen in its native unmodified form. In the past, researchers have been limited because soft materials were difficult to print with high fidelity.\u201cWe now have the ability to build constructs that recapitulate key structural, mechanical and biological properties of native tissues,\u201d says Adam Feinberg, chief technology officer and co-founder of FluidForm, which holds the license to FRESH technology from Carnegie Mellon. \u201cThere are still many challenges to overcome to get us to bioengineered 3D organs, but this research represents a major step forward.\u201dWhile the heart was used for the proof of concept, FRESH printing of collagen and other soft biomaterials is a platform with potential to support advanced scaffold platforms for a range of other tissues and organ systems, Feinberg advises.Now, FluidForm will commercialize the FRESH technology with its first product, the Trileaflet heart valve, under the name LifeSupport bioprinting support gel.Francis Collins, MD, director at the National Institutes of Health, is impressed with the advancements being made at Carnegie Mellon. \u201cWhat distinguishes the new approach is its ability to print soft biological scaffolds that set the stage for the creation of custom-made tissues and organs with unprecedented anatomical detail,\u201d he says.The complete study is published in the current issue of Science, available here.","order":0,"get_parent":{},"attributes":[],"attributesType":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"dynamicContent":""}]

Researchers make progress in 3D printing of organs, tissues

More for you